Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.

Mult Scler

Department of Neurology, University of California, San Francisco, 521 Parnassus Avenue, C-440, San Francisco, CA 94143-0114, USA.

Published: June 2004

Mitoxantrone (Novantrone) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo-controlled phase 2 trial will be outlined in this article.

Download full-text PDF

Source
http://dx.doi.org/10.1191/1352458504ms1032oaDOI Listing

Publication Analysis

Top Keywords

progressive multiple
8
multiple sclerosis
8
mitoxantrone potential
4
potential therapy
4
therapy primary
4
primary progressive
4
sclerosis mitoxantrone
4
mitoxantrone novantrone
4
novantrone drug
4
drug approved
4

Similar Publications

Background: AT-rich interaction domain 4B (ARID4B) is a transcriptional activator that regulates the phosphatidylinositol 3-kinase (PI3K)/AKT pathway in prostate cancer. However, the role of ARID4B in hepatocellular carcinoma (HCC) has remained unclear.

Methods: This study included 162 patients who had undergone primary hepatic resection for HCC between 2008 and 2019.

View Article and Find Full Text PDF

Identification of immune suppressor candidates utilizing comparative transcriptional profiling in histiocytic sarcoma.

Cancer Immunol Immunother

January 2025

Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Histiocytic sarcoma (HS) is a rare yet lethal malignancy with no established standard of care therapies. A lack of pre-clinical models limits our understanding of HS pathogenesis and identification of therapeutic targets. Canine HS shares multiple clinical and genetic similarities with human HS, supporting its use as a unique translational model.

View Article and Find Full Text PDF

The complex set of interactions between the immune system and metabolism, known as immunometabolism, has emerged as a critical regulator of disease outcomes in the central nervous system. Numerous studies have linked metabolic disturbances to impaired immune responses in brain aging, neurodegenerative disorders, and brain injury. In this review, we will discuss how disruptions in brain immunometabolism balance contribute to the pathophysiology of brain dysfunction.

View Article and Find Full Text PDF

Multi-Omics Research on Angina Pectoris: A Novel Perspective.

Aging Dis

December 2024

Department of Psycho-cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

Angina pectoris (AP), a clinical syndrome characterized by paroxysmal chest pain, is caused by insufficient blood supply to the coronary arteries and sudden temporary myocardial ischemia and hypoxia. Long-term AP typically induces other cardiovascular events, including myocardial infarction and heart failure, posing a serious threat to patient safety. However, AP's complex pathological mechanisms and developmental processes introduce significant challenges in the rapid diagnosis and accurate treatment of its different subtypes, including stable angina pectoris (SAP), unstable angina pectoris (UAP), and variant angina pectoris (VAP).

View Article and Find Full Text PDF

Osteoarthritis (OA) is a multifaceted degenerative joint disorder affected by various risk factors such as age, mechanical stress, inflammation, and metabolic influences. These elements contribute to its diverse phenotypes and endotypes, underscoring the disease's inherent complexity. The involvement of multiple tissues and their interplay further complicates OA's investigation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!